Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.
-
Zhang Y
Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
-
Coats AJS
Department of Cardiology, IRCCS San Raffaele Pisana, Rome, Italy.
-
Zheng Z
Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
-
Adamo M
Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
-
Ambrosio G
Division of Cardiology, University of Perugia School of Medicine, Perugia, Italy.
-
Anker SD
Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
-
Butler J
Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
-
Xu D
Key Laboratory for Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China.
-
Mao J
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
-
Khan MS
Department of Medicine, Cook County Hospital, Chicago, IL, USA.
-
Bai L
Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
-
Mebazaa A
Université de Paris, Paris, France; U942 Inserm - MASCOT and Department of Anaesthesia and Critical Care, University Hospitals Saint Louis-Lariboisière, APHP, Paris, France.
-
Ponikowski P
Center for Heart Diseases, University Hospital, Medical University, Wroclaw, Poland.
-
Tang Q
Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, Hubei Key Laboratory of Cardiology, Wuhan, China.
-
Ruschitzka F
University Heart Centre, University Hospital Zurich, Zurich, Switzerland.
-
Seferovic P
Clinic of Endocrinology, Diabetes and Metabolic Diseases, Belgrade University Medical Center, Belgrade, Serbia.
-
Tschöpe C
Department of Cardiology, Campus Virchow Klinikum, Charite - Universitaetsmedizin Berlin, Berlin, Germany.
-
Zhang S
Department of Cardiology, Peking Union Medical College & Chinese Academy of Medical Science, Peking Union Medical College Hospital, Beijing, China.
-
Gao C
Department of Cardiology, Henan Provincial People's Hospital, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China.
-
Zhou S
Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, China.
-
Senni M
Cardiology Division, Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.
-
Zhang J
Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
-
Metra M
Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Show more…
Published in:
- European journal of heart failure. - 2020
English
The coronavirus disease 2019 (COVID-19) pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is causing considerable morbidity and mortality worldwide. Multiple reports have suggested that patients with heart failure (HF) are at a higher risk of severe disease and mortality with COVID-19. Moreover, evaluating and treating HF patients with comorbid COVID-19 represents a formidable clinical challenge as symptoms of both conditions may overlap and they may potentiate each other. Limited data exist regarding comprehensive management of HF patients with concomitant COVID-19. Since these issues pose serious new challenges for clinicians worldwide, HF specialists must develop a structured approach to the care of patients with COVID-19 and be included early in the care of these patients. Therefore, the Heart Failure Association of the European Society of Cardiology and the Chinese Heart Failure Association & National Heart Failure Committee conducted web-based meetings to discuss these unique clinical challenges and reach a consensus opinion to help providers worldwide deliver better patient care. The main objective of this position paper is to outline the management of HF patients with concomitant COVID-19 based on the available data and personal experiences of physicians from Asia, Europe and the United States.
-
Language
-
-
Open access status
-
bronze
-
Identifiers
-
-
Persistent URL
-
https://folia.unifr.ch/global/documents/258352
Statistics
Document views: 7
File downloads: